Introduction to the Human Immunodeficiency Virus

HIV Structure and Classification What Is HIV and Why Does It Matter? Human immunodeficiency virus (HIV) is a retrovirus—a virus that uses a unique reproductive strategy involving reverse transcription to convert its genetic material into a form that can integrate into the host cell's DNA. Understanding HIV's structure, replication strategy, and how it destroys the immune system is essential for grasping both the pathology of AIDS and how modern treatments work. Viral Structure: The Key Components HIV is an enveloped virus with two concentric layers. At its core lies a single-stranded RNA genome—unlike the double-stranded DNA used by most organisms—which serves as the virus's genetic blueprint. This RNA is surrounded by several structural proteins that give HIV its characteristic shape and function. The outermost layer is the viral envelope, which is derived from the host cell membrane but studded with viral proteins. The most important of these is gp120 (glycoprotein 120), which acts as the "key" that allows HIV to recognize and bind to target cells. Just below gp120 sits gp41, a fusion protein that helps the viral and cellular membranes merge together. Inside the envelope, the viral core contains three enzymes that are absolutely critical for HIV replication: Reverse transcriptase: Converts the viral RNA into double-stranded DNA Integrase: Inserts the viral DNA into the host chromosome Protease: Cuts newly made viral proteins into functional units These three enzymes are the primary targets of modern antiretroviral drugs. How HIV Recognizes and Enters Cells HIV has evolved an elegant two-step recognition system that ensures it infects the right target cells. First, gp120 binds to CD4 receptors present on the surface of CD4⁺ T lymphocytes (which you'll learn more about below). This initial binding causes a conformational change that exposes co-receptor binding sites. These sites then engage with one of two co-receptors—either CCR5 or CXCR4—also found on the cell surface. This dual-recognition system serves an important function: it prevents accidental infection and provides a natural barrier. Some people who lack functional CCR5 receptors (a genetic variation) are naturally resistant to most strains of HIV. Once both recognition steps are complete, gp41 facilitates membrane fusion, merging the viral envelope with the host cell membrane. The viral core then releases its RNA and enzymes into the cytoplasm, initiating the replication cycle. Why HIV Destroys the Immune System HIV's Achilles' heel from the immune system's perspective is also why it's so dangerous: it directly targets CD4⁺ T lymphocytes, the master coordinators of adaptive immunity. These cells orchestrate nearly all immune responses by: Activating cytotoxic T cells to kill infected cells Helping B cells produce antibodies Coordinating inflammatory responses When HIV gradually destroys CD4⁺ T cells through infection and replication, the entire immune system loses its conductor. This progressive destruction creates a state of increasing immunodeficiency, where the body becomes vulnerable to infections and cancers that a healthy immune system would easily eliminate. The HIV Replication Cycle and Latency From Entry to Integrated DNA Once inside the cell, HIV's replication follows a characteristic sequence: Reverse Transcription: The viral enzyme reverse transcriptase uses the single-stranded RNA genome as a template to synthesize a complementary DNA strand. It then degrades the original RNA and synthesizes the second DNA strand, creating double-stranded DNA. This step is crucial because it converts the virus's genetic material into a form that can integrate into the host genome. Integration: The viral enzyme integrase recognizes specific sequences in the newly formed viral DNA and cuts both the viral DNA and the host chromosome. It then inserts the viral DNA into the break in the host chromosome, where host cell machinery repairs the cuts. Once integrated, the viral DNA becomes part of the host genome—passed on to daughter cells during cell division. Transcription and Translation: Host cell machinery recognizes the integrated viral genes and transcribes them into mRNA. The host's ribosomes then translate this mRNA into viral proteins. Some proteins serve structural functions; others are enzymes needed for viral replication. Assembly and Budding: Newly synthesized viral components gather at the cell membrane and begin to pinch off, taking a piece of the host membrane as they exit. This creates an immature, non-infectious virion—but it's not quite ready for action yet. Protease Maturation: Once the virion buds from the cell, the viral protease becomes active and cleaves the newly synthesized proteins into their functional forms. This maturation process transforms the particle into an infectious virion capable of infecting new cells. The Problem of Latency A critical challenge in HIV treatment stems from latent viral reservoirs—integrated viral DNA that remains dormant within host cells, often in long-lived CD4⁺ T cells or in tissue macrophages. These latent viruses: Are not actively producing new virions Evade detection by the immune system Are not accessible to many antiretroviral drugs Even if antiretroviral therapy reduces viral replication to undetectable levels, these latent reservoirs persist. This is why HIV requires lifelong treatment—not because ART fails to suppress the virus, but because it cannot eradicate these hidden reservoirs. Disease Progression: From Infection to AIDS The Natural Progression Without Treatment Untreated HIV infection follows a predictable pattern of progressive immunosuppression: Acute Phase (First Weeks): When initially infected, patients often experience acute HIV syndrome—a mononucleosis-like illness with fever, fatigue, and lymphadenopathy. During this phase, the virus replicates explosively and viral load surges to high levels. Simultaneously, the immune system begins to mount a response, and CD4⁺ count may temporarily fall but often recovers partially. Clinical Latency (Months to Years): After the acute phase, patients enter a period of clinical latency where few symptoms appear and CD4⁺ count stabilizes—though gradually declining. Viral replication continues, but at lower levels. This deceptively quiet period can last years if untreated, but the virus is continuously destroying CD4⁺ cells. AIDS Stage: When CD4⁺ count falls below approximately 200 cells/mm³, the infection is clinically classified as acquired immunodeficiency syndrome (AIDS). At this point, CD4⁺ cell counts are so depleted that patients become susceptible to opportunistic infections—infections caused by organisms that healthy immune systems easily control. These include: Pneumocystis pneumonia Cryptococcal meningitis Tuberculosis Cytomegalovirus infections Candida infections Additionally, patients become vulnerable to certain malignancies, particularly non-Hodgkin lymphoma and Kaposi sarcoma, because CD8⁺ T cells lose the help they need from CD4⁺ cells to monitor and eliminate abnormal cells. Antiretroviral Therapy: The Modern Standard of Care How Combination Therapy Works Modern HIV treatment is built on a simple but powerful principle: use drugs that attack different steps of the viral replication cycle simultaneously. Since HIV must complete multiple distinct steps to replicate—reverse transcription, integration, protease maturation, and others—blocking multiple steps simultaneously provides several advantages: Synergistic effect: Blocking one pathway makes it harder for the virus to escape through another Reduced resistance: The virus is far less likely to develop resistance to multiple drugs simultaneously Sustained viral suppression: If one drug's effectiveness wanes, others maintain suppression Typical ART regimens combine: One or more drugs targeting reverse transcriptase (like NRTIs or NNRTIs) An integrase inhibitor A protease inhibitor or other agent blocking viral maturation The Real-World Impact of Consistent Treatment For patients who take ART consistently and properly, the results have been transformative: Viral load becomes undetectable: With effective suppression, viral replication drops to levels below the detection limit of standard tests Immune function is preserved: CD4⁺ counts stabilize and often increase substantially, maintaining immune competence Transmission risk plummets: The concept of "undetectable = untransmittable" (U=U) reflects the finding that people with undetectable viral loads cannot sexually transmit HIV This represents one of modern medicine's greatest achievements—converting a once-fatal diagnosis into a manageable chronic disease. Why Cure Remains Elusive Despite these successes, current ART has one fundamental limitation: it cannot eradicate the latent viral reservoir. Once integrated into host DNA, latent virus is largely invisible to antiretroviral drugs and the immune system alike. If a patient stops taking ART, dormant virus can reactivate and begin replicating again, causing viral load to rebound within weeks. This is why HIV remains incurable with current technology and why lifelong therapy is necessary. However, active research into "shock and kill" strategies, therapeutic vaccines, and gene therapy offers hope for future breakthroughs. HIV Transmission and Public Health HIV spreads through three major routes: Blood Exposure: Sharing needles (during intravenous drug use), occupational needlestick injuries, and other direct blood-to-blood contact can transmit the virus. Sexual Contact: The virus can cross mucosal barriers in genital, anal, and oral tissues, making all forms of sexual contact potential transmission routes. Risk varies with sexual practice and presence of sexually transmitted infections that disrupt mucosal barriers. Mother-to-Child Transmission: An infected pregnant woman can transmit HIV to her fetus across the placenta during pregnancy, through blood exposure during delivery, or through breast milk during breastfeeding. However, modern prevention protocols have made transmission to infants rare in resourced settings. Understanding these routes is essential for public health efforts focused on prevention, testing, and treatment initiation.